[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dlbcl-nos\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dlbcl-nos":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":5},"100385614","study-of-car-t-therapy-in-older-patients-100385614",false,"NCT04300998","Study of CAR-T Therapy in Older Patients","Observational Study of Commercial Chimeric Antigen Receptor T-cell (CAR T) Therapy in Older Patients With Hematologic Malignancies and With an Embedded Pilot Study of Longitudinal Geriatric and Neurocognitive Evaluation","Inclusion Criteria:\n\n* are ≥60 years old (all cohorts)\n* have pathologically confirmed, relapsed refractory lymphoid malignancy or plasma cell disorder receiving a commercial CAR T-cell product (all cohorts)\n* able to speak and understand English (cohort 1 and 4 only)\n* have a MoCA score of less than 26 out of 30 during the GA visit by a geriatrician prior to CAR T-cell treatment (cohort 4 only)\n\nExclusion Criteria:\n\n* Any prior commercial or investigational CAR T therapy (all cohorts)\n* Current diagnosis of major Axis I psychiatric disorder (DSM-IV), major depression, bipolar disorder, or schizophrenia, as per medical records or patient report (cohort 1 only)\n* History of a neurological disorder, neurodegenerative disease, or traumatic brain injury with loss of consciousness (\\>60 minutes), as per medical records or patient report (cohort 1 only)\n* Current ongoing substance abuse and\u002For history of substance abuse, as per medical records or patient report (cohort 1 only)\n* History of CNS disease (cohort 4 only)","ALL","60 Years",{"count":19,"type":20},154,"ESTIMATED","OBSERVATIONAL","This study is being done to find out how older patients respond to CAR-T cell therapy and how the treatment affects their quality of life. This is a quality of life study and participating in the study does not involve receiving any treatment, other than the standard treatment for participants' disease.",[24,25,26,27,28,29],"Lymphoma","Refractory B-Cell Lymphoma","Lymphoma, B-Cell","DLBCL NOS","High-grade B-cell Lymphoma","Multiple Myeloma",[24,31,32,28,27,25,33,34],"CART therapy","relapsed refractory large B-cell lymphoma","19-452","Memorial Sloan Kettering Cancer Center","RECRUITING","2026-04-01",{"date":38,"type":39},"2026-04-07","ACTUAL",{"date":41,"type":39},"2020-03-04",{"date":43,"type":20},"2027-03-04",{"name":34,"class":45},"OTHER"]